title: Anti-inflammatory effects of a stabilized lipid extract of Perna canaliculus (Lyprinol).
abstract: A lipid-rich extract, prepared by supercritical fluid (CO2) extraction of freeze-dried stabilized NZ green-lipped mussel powder (Lyprinol) has shown significant anti-inflammatory (AI) activity when given to animals and humans. When treated p.o. with Lyprinol, Wistar and Dark Agouti rats developed neither adjuvant-induced polyarthritis or collagen(II)-induced auto-allergic arthritis. This was achieved with doses < NSAIDs, and 200 times < of other seed or fish oils. Lyprinol subfractions inhibited LTB4 biosynthesis by PMN in vitro, and PGE2 production by activated macrophages. Much of this AI activity was associated with omega-3 PUFAs and natural antioxidants [e.g. carotenoids]. In contrast to NSAIDs, Lyprinol is non-gastro toxic in disease-stressed rats at 300 mg/kg p.o., and does not affect platelet aggregation [human, rat]. Clinical studies, either controlled or randomized, have demonstrated very significant AI activity in patients with osteoarthritis (OA), rheumatoid arthritis (RA), asthma, and other inflammatory conditions. Lyprinol is a reproducible, stable source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.
authors.affiliation: University of California, USA.
authors.forename: G M
authors.initials: GM
authors.lastname: Halpern
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D049872:Bivalvia / Q000737:chemistry*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004333:Drug Administration Routes; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D005612:Freeze Drying; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis; D015289:Leukotrienes / Q000096:biosynthesis; D008055:Lipids / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use*; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D008519:Medicine, Traditional; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D009520:New Zealand; D010003:Osteoarthritis / Q000188:drug therapy; D010938:Plant Oils / Q000494:pharmacology / Q000627:therapeutic use; D011310:Preservatives, Pharmaceutical / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D017208:Rats, Wistar; D013644:Tartrates / Q000494:pharmacology; D014020:Tissue Extracts / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006893:Hydroxyeicosatetraenoic Acids; D015289:Leukotrienes; D008055:Lipids; D016859:Lipoxygenase Inhibitors; D010938:Plant Oils; D011310:Preservatives, Pharmaceutical; D013644:Tartrates; D014020:Tissue Extracts; C418997:lyprinol; C022022:5-hydroxy-6,8,11,14-eicosatetraenoic acid; C029768:tartaric acid